Investment
Features
FeesSafety
Academy
More
Pluang+

Rithm Capital (RITM) is notably undervalued amid sector sell-off, with a strong buy rating and $13.30 price target.

Analyst Insights
15 Sep 2026
Seeking Alpha
View Source
Bullish
Rithm Capital (RITM) is notably undervalued amid sector sell-off, with a strong buy rating and $13.30 price target.

Rithm Capital Corp. (RITM) is currently trading at a significant discount to its estimated book value, driven by its diversified portfolio including mortgage servicing rights and asset management subsidiaries. Despite a minor book value decline in Q2 2026 due to rising interest rates, RITM has shown resilience and growth over the past three years, outperforming many mortgage REIT peers. The company’s strategic acquisitions and hedging strategies position it well for various interest rate environments. Analysts recommend RITM as a strong buy with a price target of $13.30, expecting the stock to appreciate as market conditions stabilize.

Rithm Capital’s updated sector analysis offers context for real estate market trends. For readers following real estate, here is Pluang's market snapshot as of Sep 15, 2026 22:41 WIB: Among 22 US real estate stocks, 11 rose and 11 fell. Notable price changes include IRM at USD 112.14 (+0.85%), AMT at USD 178.42 (+0.84%), and SPG at USD 203.83 (-0.56%).

More News

New crypto Pepeto raises $11.23M amid Ethereum's bullish $10,000 price forecast for 2026.

New crypto Pepeto raises $11.23M amid Ethereum's bullish $10,000 price forecast for 2026.

Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...

Market News
Bullish
58 minutes ago
BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock's stake in Fagron drops below 3% after share transfers, holding 2.96% voting rights as of October 2026.

BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...

Market News
Neutral
1 hour ago
FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

FDA approves phentolamine eye drops for presbyopia, offering a new treatment for age-related near vision loss.

Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...

Market News
Bullish
1 hour ago
K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision performs 5,000 Light Adjustable Lens procedures, leading globally in this advanced vision tech.

K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...

Market News
Bullish
1 hour ago
BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock's stake in Fagron falls below 3% after share disposals, now holding 2.96% voting rights.

BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App